These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 28480956)
21. SGLT2 inhibitors and renal function. Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782 [No Abstract] [Full Text] [Related]
22. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease]. Wang YJ; Hao CM Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277 [TBL] [Abstract][Full Text] [Related]
23. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview. Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854 [TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Raskin P Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735 [TBL] [Abstract][Full Text] [Related]
25. EMPA-REG OUTCOME: The Nephrologist's Point of View. Wanner C Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179 [TBL] [Abstract][Full Text] [Related]
26. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. Riggs K; Ali H; Taegtmeyer H; Gutierrez AD Metab Syndr Relat Disord; 2015 Sep; 13(7):292-7. PubMed ID: 26125313 [TBL] [Abstract][Full Text] [Related]
27. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716 [TBL] [Abstract][Full Text] [Related]
28. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences. Singh AK; Singh R Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488 [TBL] [Abstract][Full Text] [Related]
32. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Kurosaki E; Ogasawara H Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279 [TBL] [Abstract][Full Text] [Related]
33. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
34. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Arakaki RF Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554 [TBL] [Abstract][Full Text] [Related]
35. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties? Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136 [TBL] [Abstract][Full Text] [Related]